Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
The Efficacy of Botulinum Toxin Vs. Corticosteroid for the Treatment of Refractory Plantar Fasciitis
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Western Institute for Veterans Research
- Target Recruit Count
- 62
- Registration Number
- NCT05367271
- Locations
- 🇺🇸
VA Salt Lake City Health Care System, Salt Lake City, Utah, United States
Vestibular Rehabilitation With Intratympanic Drug Therapy in Meniere's Disease
- Conditions
- Interventions
- First Posted Date
- 2022-05-02
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Combined Military Hospital Quetta
- Target Recruit Count
- 93
- Registration Number
- NCT05355610
- Locations
- 🇵🇰
CMH Quetta, Quetta, Balochistan, Pakistan
Low Dose Olanzapine to the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy in Children and Adolescents
- Conditions
- Interventions
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2022-07-28
- Target Recruit Count
- 210
- Registration Number
- NCT05346731
- Locations
- 🇷🇺
Zhukov Nikolay, Moscow, Russian Federation
Individualizing Corticosteroid Use in Pneumonia
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 24
- Registration Number
- NCT05334316
- Locations
- 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States
Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2024-03-18
- Target Recruit Count
- 126
- Registration Number
- NCT05325593
- Locations
- 🇪🇸
Hospital del Mar, Barcelona, Spain
🇪🇸Centre Sociosanitari Sant Jordi de la Vall D'Hebron, Barcelona, Spain
🇪🇸Complejo Asistencial Universitario de Burgos, Burgos, Spain
Post Operative Pain Management for ACL Reconstruction
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Rothman Institute Orthopaedics
- Target Recruit Count
- 154
- Registration Number
- NCT05316168
- Locations
- 🇺🇸
Rothman Orthopaedic Institute, Philadelphia, Pennsylvania, United States
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
- Conditions
- Interventions
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 34
- Registration Number
- NCT05308654
- Locations
- 🇺🇸
Tulane University School of Medicine /ID# 244854, New Orleans, Louisiana, United States
🇺🇸American Oncology Partners of Maryland /ID# 244858, Bethesda, Maryland, United States
🇺🇸Atrium Health Levine Cancer Institute /ID# 243420, Charlotte, North Carolina, United States
Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 66
- Registration Number
- NCT05303792
- Locations
- 🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸Logan Health Medical Center, Kalispell, Montana, United States
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Hellenic Society of Hematology
- Target Recruit Count
- 108
- Registration Number
- NCT05298683
- Locations
- 🇬🇷
General Hospital of Athens "Evangelismos", Athens, Greece
🇬🇷Anticancer Oncology Hospital of Athens "Agios Savvas", Athens, Greece
🇬🇷General Hospital of Athens "Alexandra", Athens, Greece
Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05293509
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.